Mundipharma's Mundesine approved in Japan

Mundipharma International Ltd. (Cambridge, U.K.) said Japan's Ministry of Health, Labor and Welfare approved Mundesine forodesine (BCX-1777) to treat relapsed or refractory peripheral T cell lymphoma. The approval is the first in the world for the purine nucleoside phosphorylase (PNP) inhibitor, the company said.

Mundipharma did not respond to inquiries regarding Mundesine's launch or pricing. In a statement, the company said it is working to ensure access in Japan "as early as possible."...